Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -468.17% is 77% above its 1-year average of -2008.10%, near the high end of its 1-year range (-3009.52%–-468.17%).
76.69% above its 12-month average of -2008.10%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3009.52%.
EBITDA MARGIN
-468.17%
EBITDA MARGIN AVG TTM
-2008.10%
EBITDA MARGIN AVG 3Y
-2008.10%
EBITDA MARGIN AVG 5Y
-2008.10%
EBITDA MARGIN AVG 10Y
-1835.26%
EBITDA MARGIN AVG 15Y
-203.30%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+76.69%
CURRENT VS 3Y AVG
+76.69%
CURRENT VS 5Y AVG
+76.69%
CURRENT VS 10Y AVG
+74.49%
CURRENT VS 15Y AVG
-130.28%
CURRENT VS 20Y AVG
N/A
Cocrystal Pharma, Inc.
Market Cap
$15.30M
EBITDA Margin
-468.17%
TTM Avg
-2008.10%
3Y Avg
-2008.10%
5Y Avg
-2008.10%
Market Cap
$15.20M
EBITDA Margin
-29916.57%
TTM Avg
-29916.57%
3Y Avg
-29916.57%
5Y Avg
-29916.57%
Market Cap
$15.20M
EBITDA Margin
-61.90%
TTM Avg
-71.95%
3Y Avg
-80.60%
5Y Avg
-87.82%
Market Cap
$15.91M
EBITDA Margin
-14633.33%
TTM Avg
-7486.14%
3Y Avg
-4543.27%
5Y Avg
-3157.51%
Market Cap
$16.22M
EBITDA Margin
-13679.31%
TTM Avg
-8051.39%
3Y Avg
-4553.85%
5Y Avg
-5076.49%
Market Cap
$14.28M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$16.54M
EBITDA Margin
-579.88%
TTM Avg
-374.35%
3Y Avg
-344.55%
5Y Avg
-411.92%
Market Cap
$16.58M
EBITDA Margin
-82.81%
TTM Avg
-187.23%
3Y Avg
-342.47%
5Y Avg
-369.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | $15.30M | -468.17% | -2008.10% | -2008.10% | -2008.10% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.20M | -29916.57% | -29916.57% | -29916.57% | -29916.57% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.20M | -61.90% | -71.95% | -80.60% | -87.82% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | -14633.33% | -7486.14% | -4543.27% | -3157.51% |
| BioCardia, Inc. (BCDA)vs › | $16.22M | -13679.31% | -8051.39% | -4553.85% | -5076.49% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.54M | -579.88% | -374.35% | -344.55% | -411.92% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.58M | -82.81% | -187.23% | -342.47% | -369.32% |
| IN8bio, Inc. (INAB)vs › | $13.62M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | -855.47% | -475.86% | -335.10% | -307.83% |
Gross Margin
0.0%
EBITDA Margin
-468.2%
Operating Margin
0.0%
Net Margin
-3011.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3009.52% |
| 2026-03-31 | -1006.67% |
| 2020-12-31 | -278.63% |
| 2020-09-30 | -544.99% |
| 2020-06-30 | -615.88% |
| 2020-03-31 | -418.87% |
| 2019-12-31 | -11914.43% |
| 2019-09-30 | -362.60% |
| 2019-06-30 | -258.11% |
| 2019-03-31 | 57.11% |
| 2015-12-31 | 56812.82% |
| 2015-09-30 | -14770.83% |
| 2015-06-30 | -13977.78% |
| 2015-03-31 | -7862.96% |
| 2014-12-31 | -17944.44% |
| 2013-09-30 | -12.56% |
| 2013-06-30 | -32.14% |
| 2013-03-31 | -43.93% |
| 2012-12-31 | -66.88% |
| 2012-09-30 | 9.89% |
| 2012-06-30 | 7.87% |
| 2012-03-31 | -13.58% |
| 2011-12-31 | -16.95% |
| 2011-09-30 | -51.16% |
| 2011-06-30 | -11.40% |
| 2011-03-31 | -0.09% |
| 2010-09-30 | -0.36% |
| 2010-06-30 | -0.66% |
